Population pharmacokinetics of NNZ-2566 in healthy subjects

• Published in: European journal of pharmaceutical sciences Vol. 109; pp. S98 - S107
• Main Authors: Oosterholt, Sean P., Horrigan, Joseph, Jones, Nancy, Glass, Larry, Della Pasqua, Oscar
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.11.2017
• Subjects: Administration, Intravenous; Administration, Oral; Adult; Biological Availability; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; First-time-in-humans; Healthy Volunteers; Humans; Male; Meta-Analysis as Topic; Metabolic Clearance Rate; Modelling and simulation; NNZ-2566; Oligopeptides - administration & dosage; Oligopeptides - pharmacokinetics; Phase I; Population pharmacokinetics; Rare diseases; Tissue Distribution; Trofinetide; Young Adult; Rare diseases; NNZ-2566; Population pharmacokinetics; Phase I; First-time-in-humans; Modelling and simulation; Trofinetide

NNZ-2566 is a novel, small molecule being developed as a treatment for cognitive impairment in different CNS conditions, including Rett and Fragile-X syndrome, both of which are associated with moderate to severe neurodevelopmental disorder. In the current study we characterise the population pharma...